Crossmark

Prognostic impact and site-specific efficacy of systemic therapies in locally advanced or metastatic urothelial carcinoma: in an era of expanding therapeutic options

Crossref DOI link: https://doi.org/10.1007/s10147-025-02919-7

Published Online: 2025-11-15

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yamamoto, Shoma

Kato, Minoru

Matsue, Taisuke

Yukimatsu, Nao

Takeyama, Yuji

Otoshi, Taiyo

Yamasaki, Takeshi

Kuratsukuri, Katsuyuki

Uchida, Junji
License Information

Text and Data Mining valid from 2025-11-15

Version of Record valid from 2025-11-15
More Information

Article History

Received: 8 September 2025

Accepted: 3 November 2025

First Online: 15 November 2025

Declarations

:

: Minoru Kato has received speaking and lecture fees from Astellas Pharma, Merck KGaA, Ono Pharmaceutical Co Ltd, Bristol-Myers Squibb Company, and Merck Sharp and Dohme UK Ltd outside the submitted work. The other authors declare that they have no conflict of interest.

: This retrospective, single-center study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Osaka Metropolitan University Hospital (approval no. 2025–016). Written informed consent was waived due to the retrospective nature of the study and the public disclosure of relevant study information.

: Not applicable.

Document is current

Any future updates will be listed below